Early predictors of refractory status epilepticus: An international two-center study

European Journal of Neurology

Volumn 22, Issue 1, 2015, Pages 79-85

  Sutter, R ^a,b,c   Kaplan, P W ^c   Marsch, S ^a   Hammel, E M ^a   Ruegg S ^a   Ziai, W C ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Epilepsy; Neurocritical care; Outcome; Refractory status epilepticus; Risk stratification

Indexed keywords

SERUM ALBUMIN; ANTICONVULSIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMA; CONSCIOUSNESS; DISEASE SEVERITY ASSESSMENT; EPILEPTIC STATE; EXTERNAL VALIDITY; FEMALE; HOSMER LEMESHOW GOODNESS OF FIT TEST; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REFRACTORY STATUS EPILEPTICUS; SCORING SYSTEM; STATUS EPILEPTICUS SEVERITY SCORE; STUPOR; VALIDATION STUDY; BLOOD; CLINICAL TRIAL; DRUG RESISTANCE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATUS EPILEPTICUS;

AGED; ANTICONVULSANTS; COMA; DRUG RESISTANCE; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; STATUS EPILEPTICUS; STUPOR;

EID: 84923069370     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12531     Document Type: Article

References (33)

1. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59: 205-210.
2. Stecker MM, Kramer TH, Raps EC, et al. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998; 39: 18-26.
3. Sutter R, Marsch S, Fuhr P, et al. Mortality and recovery from refractory status epilepticus in the ICU: a 7-year observational study. Epilepsia 2013; 54: 502-511.
4. Agan K, Afsar N, Midi I, et al. Predictors of refractoriness in a Turkish status epilepticus data bank. Epilepsy Behav 2009; 14: 651-654.
5. Holtkamp M, Othman J, Buchheim K, et al. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005; 76: 534-539.
6. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia 2010; 51: 251-256.
7. Sutter R, Grize L, Fuhr P, et al. Acute phase proteins and mortality in status epilepticus: a five-year observational cohort study. Crit Care Med 2013; 41: 1526-1533.
8. Sutter R, Kaplan PW, Rüegg S. Outcome predictors for status epilepticus - what really counts. Nat Rev Neurol 2013; 9: 525-534.
9. Rossetti AO, Logroscino G, Milligan TA, et al. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008; 255: 1561-1566.
10. Sutter R, Kaplan PW, Rüegg S. Independent external validation of the Status Epilepticus Severity Score. Crit Care Med 2013; 41: e475-e479.
11. Rudin D, Grize L, Schindler C, et al. High prevalence of nonconvulsive and subtle status epilepticus in an ICU of a tertiary care center: a three-year observational cohort study. Epilepsy Res 2011; 96: 140-150.
12. Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in status epilepticus - risk or rescue? A six-year cohort study. Neurology 2013; 82: 656-664.
13. Kaplan PW. No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: 'the cure may be worse than the disease'). Neurophysiol Clin 2000; 30: 377-382.
14. Kowalski RG, Ziai WC, Rees RN, et al. Third-line antiepileptic therapy and outcome in status epilepticus: the impact of vasopressor use and prolonged mechanical ventilation. Crit Care Med 2012; 40: 2677-2684.
15. Sutter R, Tschudin-Sutter S, Grize L, et al. Associations between infections and clinical outcome parameters in status epilepticus: a retrospective 5-year cohort study. Epilepsia 2012; 53: 1489-1497.
16. Young GB, Jordan KG, Doig GS. An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: an investigation of variables associated with mortality. Neurology 1996; 47: 83-89.
17. Sutter R, Tschudin-Sutter S, Grize L, et al. Acute phase proteins and white blood cell levels for prediction of infectious complications in status epilepticus. Crit Care 2011; 15: R274.
18. Commission on Epidemiology and Prognosis of the International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993; 34: 592-596.
19. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17: 3-23.
20. Leppert D, Stöckli HR, Fuhr P. Richtlinien zur Behandlung des Status epilepticus. Schweiz Ärztetzeitung 2005; 86: 1-14.
21. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010; 17: 348-355.
22. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40: 120-122.
23. Hanley DF, Kross JF. Use of midazolam in the treatment of refractory status epilepticus. Clin Ther 1998; 20: 1093-1105.
24. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
25. Vezzani A, French J, Bartfai T, et al. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7: 31-40.
26. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-1482.
27. Carter AM, Catto AJ, Mansfield MW, et al. Predictive variables for mortality after acute ischemic stroke. Stroke 2007; 38: 1873-1880.
28. Gillum RF, Makuc DM. Serum albumin, coronary heart disease, and death. Am Heart J 1992; 123: 507-513.
29. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46: 1029-1035.
30. Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001; 42: 714-718.
31. Sutter R, Fuhr P, Grize L, et al. Continuous video-EEG monitoring increases detection rate of nonconvulsive status epilepticus in the ICU. Epilepsia 2011; 52: 453-457.
32. Drislane FW, Blum AS, Lopez MR, et al. Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours. Epilepsia 2009; 50: 1566-1571.
33. Towne AR. Epidemiology and outcomes of status epilepticus in the elderly. Int Rev Neurobiol 2007; 81: 111-127.